[The profile of drug addicts attending the Sainte Marguerite University Hospital in Marseille analysis of the active file from 1996 to 2001].
OBJECTIVE
Present the evolution in the characteristics of drug addicts treated in the Addictions-Sud centre (Marseille) between 1996 and 2001, and compare the profile of patients according to the substitution therapy prescribed.


METHODS
Descriptive analysis of the data collected from the inclusion questionnaire of patients seen during a hospital consultation in the centre and registered in a substitution program (n = 585 patients).


RESULTS
In our active file, the use of heroin and injections has decreased since 1996, whereas the consumption of cocaine and above all amphetamines and LSD has greatly increased. When treated, 60% of the patients were administered methadone and 40% BHD. (The patients included in the methadone program (n = 348) were considerably older and frequently HIV or hepatitis C-infected than those treated with BHD (n = 229)). The proportion of patients who had previously undertaken withdrawal or substitution measures, and who continued to inject drugs, was greater in the group of patients in the methadone program. The presence of depression, psychotic disorders and anxiety was noted respectively in 46, 30 and 24% of the patients treated.


CONCLUSIONS
Today, it is crucial that information on the treatment of drug addicts should be reinforced, so as to measure the progression of the problems encountered, specify the indications of the two substitution products currently prescribed and understand the impact they have on the psychiatric disorders and viral pathologies frequently noted in drug addicts.
Lançon
C
C
Addictions-Sud, C.H.U. Sainte-Marguerite, Marseille (13). christophe.lancon@mail.ap-hm.fr
Jaquet
I
I
Labrune
N
N
Bartolo
K
K
De Stopeleire
C
C
Auquier
P
P
D000328:Adult; D017677:Age Distribution; D002047:Buprenorphine / Q000627:therapeutic use*; D015331:Cohort Studies; D062787:Drug Overdose / Q000453:epidemiology; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000453:epidemiology; D006213:Hallucinogens / Q000008:administration & dosage; D006526:Hepatitis C / Q000453:epidemiology; D006785:Hospitals, University; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000008:administration & dosage; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology; D008691:Methadone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D011632:Public Assistance / Q000706:statistics & numerical data; D019966:Substance-Related Disorders / Q000453:epidemiology* / Q000534:rehabilitation*; D013406:Suicide, Attempted / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires
D006213:Hallucinogens; D009292:Narcotic Antagonists; D009294:Narcotics; D002047:Buprenorphine; D008238:Lysergic Acid Diethylamide; D008691:Methadone